P

Assignee

ALMIRALL SA

41 patents

Top patents by PatentIndex Score

US7750023B2Jul 6, 2010

Quinuclidine derivatives and medicinal compositions containing the same

ALMIRALL SA27 citations96
US7897617B2Mar 1, 2011

Quinuclidine derivatives and medicinal compositions containing the same

ALMIRALL SA21 citations95
US9333195B2May 10, 2016

Quinuclidine derivatives and medicinal compositions containing the same

ALMIRALL SA8 citations92
US9056100B2Jun 16, 2015

Quinuclidine derivatives and medicinal compositions containing the same

ALMIRALL SA9 citations92
US8802699B2Aug 12, 2014

Quinuclidine derivatives and medicinal compositions containing the same

ALMIRALL SA12 citations92
US7964615B2Jun 21, 2011

Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor

ALMIRALL SA15 citations90
US10034867B2Jul 31, 2018

Quinuclidine derivatives and medicinal compositions containing the same

ALMIRALL SA2 citations84
US9687478B2Jun 27, 2017

Quinuclidine derivatives and medicinal compositions containing the same

ALMIRALL SA5 citations84
US7776879B2Aug 17, 2010

Quinuclidine carbamate derivatives and their use as M3 antagonists

ALMIRALL SA12 citations83
US9233108B2Jan 12, 2016

Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities

ALMIRALL SA9 citations82
USRE46417EMay 30, 2017

Quinuclidine derivatives and their use as muscarinic M3 receptor ligands

ALMIRALL SA4 citations80
US9562039B2Feb 7, 2017

Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities

ALMIRALL SA10 citations78
US7893087B2Feb 22, 2011

Quinuclidine derivatives and medicinal compositions containing the same

ALMIRALL SA5 citations74
US9757383B2Sep 12, 2017

Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities

ALMIRALL SA2 citations71
US9549934B2Jan 24, 2017

Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities

ALMIRALL SA2 citations71
US10005771B2Jun 26, 2018

Bicyclic derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities

ALMIRALL SA2 citations70
US9643961B2May 9, 2017

Cyclohexylamine derivatives having β2 adrenergic antagonist and M3 muscarinic antagonist activities

ALMIRALL SA2 citations70
US10759793B2Sep 1, 2020

2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors

ALMIRALL SA3 citations69
US10434268B2Oct 8, 2019

Inhalation device for powdered drugs

ALMIRALL SA2 citations69
US9579316B2Feb 28, 2017

Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscarinic receptor antagonist and β2 adrenergic receptor agonist activities

ALMIRALL SA3 citations67
US9254262B2Feb 9, 2016

Dosage and formulation

ALMIRALL SA6 citations65
US10588895B2Mar 17, 2020

Quinuclidine derivatives and medicinal compositions containing the same

ALMIRALL SA0 citations63
US7879874B2Feb 1, 2011

Quinuclidine derivatives and medicinal compositions containing the same

ALMIRALL SA3 citations63
US8820321B2Sep 2, 2014

Storage system for powdered pharmaceuticals, and inhaler equipped with this system

ALMIRALL SA2 citations62
US8375940B2Feb 19, 2013

Storage system for powdered pharmaceuticals and inhaler equipped with this system

ALMIRALL SA1 citations62
US9907807B2Mar 6, 2018

Topical pharmaceutical compositions

ALMIRALL SA2 citations59
US8051851B2Nov 8, 2011

Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler

ALMIRALL SA2 citations59
US9518050B2Dec 13, 2016

Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity

ALMIRALL SA2 citations57
US9737520B2Aug 22, 2017

Aclidinium for use in improving the quality of sleep in respiratory patients

ALMIRALL SA4 citations56
US11000517B2May 11, 2021

Dosage and formulation

ALMIRALL SA0 citations54
US10300072B2May 28, 2019

Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities

ALMIRALL SA0 citations51
US7954492B2Jun 7, 2011

Pharmaceutical powder cartridge, and inhaler equipped with same

ALMIRALL SA0 citations49
US10085974B2Oct 2, 2018

Dosage and formulation

ALMIRALL SA1 citations44
US9388189B2Jul 12, 2016

Pyrrolotriazinone derivatives as PI3K inhibitors

ALMIRALL SA1 citations41
US10828433B2Nov 10, 2020

Inhalation device for powdered drugs

ALMIRALL SA0 citations38
US10512740B2Dec 24, 2019

Inhalation device for powdered drugs

ALMIRALL SA0 citations38
US9346759B2May 24, 2016

Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor

ALMIRALL SA0 citations38
US10214509B2Feb 26, 2019

Amino-substituted heterocyclic derivatives as sodium channel inhibitors

ALMIRALL SA0 citations37
US10456390B2Oct 29, 2019

Combinations comprising MABA compounds and corticosteroids

ALMIRALL SA0 citations36
US10173985B2Jan 8, 2019

Aminoindazole derivatives as sodium channel inhibitors

ALMIRALL SA0 citations33
US11602515B2Mar 14, 2023

Pharmaceutical compositions comprising dimethyl fumarate

ALMIRALL SA0 citations31